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Background
To evaluate inter-multidisciplinary team agreement for the diagnosis of diffuse parenchymal lung disease (DPLD).
Methods
Seven multidisciplinary meetings (MDTMs) consisting of at least one clinician, radiologist and pathologist, from 7 different countries evaluated 70 cases of diffuse lung disease in a two-stage process. First, the clinician, radiologist and pathologist (when lung biopsy was performed) evaluated each case and chose likelihoods (censored at 5% and summing to 100% in each case) for each of their differential diagnoses, without inter-disciplinary consultation. A full MDTM with review of all clinical, radiologic and pathologic data followed this. Interobserver agreement and inter-MDTM agreement for diagnosis was calculated using Cohen's kappa coefficient or weighted kappa coefficient where appropriate.
Findings
Inter-MDTM agreement for first choice diagnoses was acceptable (κ = 0·50).
Idiopathic pulmonary fibrosis made up 18% of all MDTM first choice diagnoses.
Diagnostic likelihoods for MDTM differential diagnoses were converted to a 5-point scale (0 = condition not included in the differential diagnosis, 1 = low probability (5-25%), 2 = intermediate probability (30-65%), 3 = high probability (70-95%), and 4 = pathognomonic (100%)). Inter-MDTM agreement on diagnostic likelihoods was good for idiopathic pulmonary fibrosis (IPF) (κw = 0·71) and connective tissue disease related interstitial lung disease (CTD-ILD) (κw = 0·73), only moderate for non-specific interstitial pneumonia (NSIP) (κw = 0·42) and poor for hypersensitivity pneumonitis (HP) (κw = 0·29). MDTMs, clinicians and radiologists respectively gave high confidence diagnoses of IPF (>65% likelihood) in 77·3%, 64·6% and 66·3% of cases.
The prognostic significance of a first choice diagnosis of IPF versus not IPF was evaluated for MDTMs, clinicians and radiologists. Greater prognostic separation was demonstrated for an MDTM diagnosis of IPF as compared to individual clinician's diagnosis of IPF in 5/7 MDTMs, radiologist's diagnosis of IPF in 4/7 MDTMs.
Interpretation
Agreement between MDTMs for diagnosis in diffuse lung disease is acceptable and good for a diagnosis of IPF. This is validated by the greater prognostic separation of an IPF diagnosis made by MDTMs as compared to individual clinicians or radiologists.
Furthermore, MDTMs made the diagnosis of IPF with higher confidence and more frequently than clinicians or radiologists. MDTM agreement for diagnosis of NSIP and hypersensitivity pneumonitis is poor, indicating a need for international consensus on diagnostic criteria for these diseases.
Introduction
Diffuse parenchymal lung disease (DPLD) represents a diverse and challenging group of pulmonary disorders with varied prognoses and different management options. A consistent diagnostic approach to these diseases is essential if clinical trial data is to be reliably applied to individual patients. With the recent licensing of two new anti-fibrotic idiopathic pulmonary fibrosis (IPF) therapies, accurate and consistent diagnosis of IPF is of particular importance if clinical benefit is to be achieved 1,2 . In 2002, a joint statement by the American Thoracic Society (ATS) and the European Respiratory Society (ERS) on the classification of the idiopathic interstitial pneumonias (IIPs) advocated a multidisciplinary diagnostic approach involving integration of clinical, radiologic and, when lung biopsy material is available, pathologic data 3 . This approach has been emphasised by several studies in recent years and was re-stated in the 2013 ATS/ERS update on the IIPs [4] [5] [6] [7] [8] . Although this recommendation specifically applies to IIP, the multidisciplinary approach has been widely adopted as the diagnostic gold standard for DPLD in general 5, 7 . Several studies have evaluated interobserver agreement for diagnosis in the setting of DPLD [5] [6] [7] 9 , but most predate the 2013 ATS/ERS IIP classification update, the 2011 ATS/ERS/JRS/ALAT statement on the diagnosis and management of IPF and the availability of novel anti-fibrotic IPF drugs, all of which may impact decisions on diagnosis 1,2,4,10 . Furthermore, many of these studies focus on individual observers rather than agreement between multidisciplinary teams (MDTs) [5] [6] [7] 9, 11 . In this study, we evaluated the level of inter-MDTM diagnostic agreement between seven international centres. different countries (Denmark, France, Italy, Japan, Netherlands, Portugal and the United Kingdom), each with specialist expertise in the diagnosis and management of DPLD, were invited to participate in the study. The only prerequisite for participation was that each MDT had a regular multidisciplinary meeting for DPLD in place with consistent attendance by at least one clinician, radiologist and pathologist.
Methods
Patient and Multidisciplinary team selection
Evaluation of cases
The evaluation of each of case took place in two stages· 1. First, clinicians, radiologists and pathologists were required to review the cases independently without inter-specialty consultation. Clinicians had access to all the presenting clinical information (age, gender, smoking history, history of established connective tissue disease (CTD), symptoms including symptoms suggestive of a CTD, autoantibody profile, exposure history, medications at presentation, bronchoalveolar lavage result if performed, and ACE level if performed), pulmonary function tests and HRCT (without access to the original HRCT report). Radiologists and pathologists had access only to the age, gender and smoking history for the patient, and the HRCT (radiologist) or digitized surgical lung biopsy slides (pathologist) at presentation. Specifically, pathologists had access to all the pathology data that was available in the form of digitized slides (in .svs format) and were viewed using Aperio ImageScope 12·3 viewing software. This digital viewing application has all the imaging functionality normally available to pathologists in routine clinical practice and is used by the host institution to evaluate cases referred from outside institutions for opinions.
For each patient, observers were required to select up to 5 differential diagnoses and provide a diagnostic likelihood (censored at 5% and summing to 100% in each case) from a drop-down menu of diffuse lung diseases (Appendix, Table A1 ). The only stipulation was that diagnoses were considered in the context of the current ATS/ERS classification and terminology for the IIPs 4 · 2. Second, the clinician, radiologist and pathologist convened as an MDT and reviewed the cases together, again providing up to 5 diagnoses with diagnostic likelihoods (also censored at 5% and summing to 100% in each case). All the clinical information supplied in the first stage, pulmonary function tests and HRCT at presentation as well as digitized surgical lung biopsy slides were available to the MDT for review.
Outcome
As a means of validating the diagnosis made by MDTM versus individual specialists, the mortality of each groups' diagnosis of IPF was compared. This was achieved by separating the entire cohort into a binary IPF diagnosis category (IPF and not IPF) for each MDTM, clinician and radiologist based upon assigned diagnoses. The survival period for each patient was calculated from the date of referral to the host institution to the minimum of date of death, date the patient was last known to be alive or Cohen's kappa coefficient (κ) was used to evaluate interobserver and inter-MDTM agreement for diagnosis. Cohen's weighted kappa coefficient (κw) was used to evaluate interobserver agreement and inter-MDTM agreement for an estimation of the probability of each diagnosis. In order to do this, the percentage diagnostic likelihood given for each diagnosis was converted to a 5 point scale (0-4), representing clinically useful probabilities: 0 = condition not included in the differential diagnosis, 1 = low probability (5-25%), 2 = intermediate probability (30-65%), 3 = high probability (70-95%), and 4 = pathognomonic (100%). For example, if the differential diagnoses given by an MDT were IPF (65% diagnostic likelihood), NSIP (25% diagnostic likelihood) and hypersensitivity pneumonitis (10% diagnostic likelihood), the probability grades for IPF, NSIP and hypersensitivity pneumonitis for this case would be 2, 1 and 1 respectively. Weighted kappa values were calculated between paired observers (for statements of interobserver agreement), and between paired MDTs (for statements of inter-MDTM agreement) and expressed as median values with interquartile ranges for all unique combinations of pairs (21 for 7 observers or 7 MDTs). Weighting the Kappa coefficient allowed the degree of disagreement to be quantified by assigning greater emphasis to large differences between scores. Weighted kappa coefficients were categorized as follows: poor (0 < κw ≤ 0·20), fair (0·20 < κw ≤ 0·40), moderate (0·40 < κw ≤ 0·60), good (0·60 < κw ≤ 0·80) and excellent (0·80 < κw ≤ 1·00). This approach has been used in previous investigations of interobserver agreement for diagnosis in diffuse lung diseases 9,11 · In addition to the above, in each case the first choice diagnosis was considered "low confidence" (diagnostic likelihood <70%), or "high confidence" (70% or greater diagnostic likelihood). These categories were based on the diagnostic likelihood categories used to assess the clinical probability of pulmonary embolism in the PIOPED study 12 .
Univariate Cox regression analysis was used to identify associations between mortality and MDTM, clinician and radiologist diagnoses in terms of IPF versus "not Role of the funding source:
The sponsors of the study did not have any role in the design, data collection, analysis and interpretation, nor in the writing of the report. The corresponding author had full access to all of the data and the final responsibility to submit for publication. Table A2 . Of note, thirteen (19%) had an established diagnosis of a connective tissue disease at the time of presentation to the host institution and 22/70 (34·1%) underwent surgical lung biopsy at the host institution. In cases where surgical lung biopsy was not performed (48/70), a confident diagnosis had been made without the need for surgical lung biopsy material.
Results
Patient population
Vital status was known for all patients at the end of the study period. These 70 patients resulted in the assignment of 490 first choice MDTM diagnoses (70 patients evaluated by 7 MDTMs). First choice diagnoses are shown in Table 2 . The NSIP/OP overlap ILD category was combined with the NSIP category and diagnosis categories whose frequency was less that 10% of the total number of first choice diagnoses were combined into an 'others' diagnosis category. The final diagnosis categories were then as follows: CTD related ILD (n=146/490, 27·8%), IPF (n=88/490, 18·0%), idiopathic NSIP (n=50/490, 10·2%), hypersensitivity pneumonitis (n=46/490, 9·4%) and others (n=160/490, 32·7%). Subsequent analyses focused on these four primary diagnosis categories.
Inter-multidisciplinary team and inter-observer agreement for first choice diagnosis
Inter-MDTM agreement and interobserver agreement (for clinicians, radiologists and pathologists) for first choice diagnosis is shown in Table 3 . Overall inter-MDTM agreement for first choice diagnosis was moderate (κ = 0·50). Inter-MDTM agreement for a first choice diagnosis of IPF was good (κ = 0·60), for a first choice diagnosis of CTD related ILD also good (κ = 0·64), but poor for first choice diagnoses of idiopathic NSIP (κ = 0·25) and hypersensitivity pneumonitis (κ = 0·24). On subgroup analysis in patients in whom lung biopsy was not performed (n=48/70, 68·6%), overall inter-MDTM agreement for diagnosis was greater (κ = 0·57) with inter-MDTM agreement for first choice diagnoses of IPF, CTD related ILD and hypersensitivity pneumonitis also greater. Overall inter-observer agreement among clinicians for first choice diagnosis was moderate (κ = 0·45) and fair between radiologists (κ = 0·33) and pathologists (κ = 0·31) ( Table 3. ).
Inter-multidisciplinary team and inter-observer agreement for diagnosis probabilities
There was fair to good inter-MDTM agreement on the estimation of diagnostic likelihood of the 4 most prevalent diagnoses as shown in Table 4 . In particular, inter-MDTM agreement on the diagnostic likelihood of IPF was good (κw= 0·71, IQR 0·64-0·77), and good for CTD related ILD (κw= 0·73, IQR 0·68-0·78) but moderate for idiopathic NSIP (κw = 0·41 IQR 0·37-0·49) and fair for hypersensitivity pneumonitis (κw = 0·29 IQR 0·24-0·40). Subgroup analysis of inter-MDTM agreement on the estimation of diagnostic likelihood of IPF in patients without lung biopsy was good (κw = 0·78 IQR 0·74-0·83).
Agreement between clinicians on the probability of a diagnosis of IPF or CTDrelated ILD was superior to agreement on the probability of a diagnosis of idiopathic NSIP or hypersensitivity pneumonitis. Agreement between radiologists or pathologists on the probability of a diagnosis of IPF was superior to agreement on the probability of a diagnosis of CTD-related ILD, idiopathic NSIP or hypersensitivity pneumonitis.
Subgroup analysis of inter-MDTM agreement in patients without an established diagnosis of a connective tissue disease.
At the time of patient selection, 13/70 (18·6%) patients had an established diagnosis of a CTD (systemic sclerosis = 7, rheumatoid arthritis = 3, Sjögren's syndrome = 2, mixed connective tissue disease = 1). In order to investigate if high agreement in these 13 cases caused a spurious increase in agreement on non-CTD diagnoses and in particular, impacting agreement on a diagnosis of IPF, a subgroup analysis was performed in the remainder of the cohort (n=57/70, 81·4%). On this analysis, although inter-MDTM agreement for a first choice diagnosis of CTD related ILD decreased (κ = 0.42), no significant change in inter-MDTM agreement was observed for a first choice diagnosis of IPF (κ = 0·58), idiopathic NSIP (κ = 0·24) or hypersensitivity pneumonitis (k = 0·23) (Appendix , Table A2 ).
Diagnostic confidence for first choice diagnoses
A total of 347/490 (70·1%) first choice MDT diagnoses were made with high confidence (diagnostic likelihood 70-95% = high confidence, 100% = pathognomonic). A review of the cases where the pathologists gave a first choice diagnosis of IPF (15/154 cases, 154 = 22 cases x 7 pathologists) was performed to ascertain if, in cases where surgical lung biopsy was performed and the first choice pathologic diagnosis was IPF, the final MDTM diagnosis was usually IPF. In 6/15 cases, despite the pathologist giving a first choice diagnosis of IPF, the final MDTM first choice diagnosis was not IPF. Furthermore, in only 2/15 cases, was IPF not already suggested by either the clinician or radiologist in that MDTM (Table A5) .
Evaluation of the prognostic significance of an MDTM diagnosis of IPF
On univariate Cox regression analysis, the multidisciplinary distinction between IPF and other diagnoses demonstrated non-significant trends toward greater prognostic separation (as judged by hazard ratio p values) than the clinician distinction (in 5/7 groups) or the radiologist distinction (in 4/7 groups) ( Table 5 A strength of our findings is that the greater agreement on multidisciplinary diagnosis is mirrored by the trend toward greater prognostic separation of a multidisciplinary distinction between IPF and other diagnoses when compared to the clinicians' or radiologists' distinction. To demonstrate this, patients were necessarily selected from 2010 to allow an analysis of 5-year survival. An added advantage of this approach was that these patients were referred in a pre-antifibrotic drug era, therefore mortality differences between IPF and non-IPF patients were not confounded by antifibrotic therapy. The fact that trends are present but inconclusive may reflect powering limitations but may also indicate that multidisciplinary discussion adds prognostic value in the sub-group of patients in which there is significant diagnostic uncertainty
In contrast to those with IPF, many patients with non-IPF interstitial lung diseases are not covered by evidence-based diagnostic guidelines therefore diagnosis is driven by clinical reasoning and analysis of all available data in a multidisciplinary setting. In these situations, a level of disagreement between MDTMs is predictable and borne out by the poor level of inter-MDTM agreement in the current study for diagnoses of NSIP and hypersensitivity pneumonitis 4, [14] [15] [16] . In particular, it is well recognised that the diagnosis of hypersensitivity pneumonitis can be challenging as it relies on an array of data, none of which is definitive when considered in isolation 15 , and at least on HRCT, patterns of NSIP, UIP or organising pneumonia may be the sole expressions of this disease [16] [17] [18] [19] . The poor MDTM agreement for the diagnosis of hypersensitivity pneumonitis in the current study highlights an urgent need for international consensus on what hypersensitivity pneumonitis actually is.
Our use of the weighted kappa to investigate inter-MDTM and interobserver agreement on diagnostic probabilities is similar to other studies of diagnostic agreement, but warrants particular consideration 9 . Converting the diagnostic likelihoods to a 5-point probability scale enabled examination of the range of diagnostic likelihoods from minimal likelihood to pathognomonic using the weighted kappa. As excluding IPF is as important as making a diagnosis of IPF, this methodology has allowed us to demonstrate that there is good agreement on the likelihood of IPF and as stated previously, this reflects consistent application of established diagnostic guidelines for this disease. In contrast, MDTM agreement on the likelihood of hypersensitivity pneumonitis was poor, reinforcing the view that MDTMs were unclear on how this diagnosis is made.
Two separate observations from our study warrant further discussion. First, 13 patients had an established diagnosis of a connective tissue disease at presentation.
However, following MDT evaluation, a CTD diagnosis was constructed in an additional 8 cases or more by five of the seven MDTMs based on presenting clinical symptoms and serology. Separating patients with IIP from those with CTD related ILD can be challenging -some patients present with subtle clinical features or serological abnormalities which suggest an autoimmune process but do not meet established criteria for a specific CTD [20] [21] [22] . Recently an ERS/ATS task force was formed in order to establish consensus on how to classify these patients and a set of diagnostic criteria have been suggested [23] [24] [25] . Following removal of patients with an established diagnosis of CTD, our subgroup analysis demonstrated acceptable levels of agreement on CTD related ILD (in contrast to hypersensitivity pneumonitis), underlying the importance of reaching international consensus on definitions.
Furthermore, the high frequency of CTD related ILD diagnoses made in the current study highlights the importance of formal rheumatology input within the MDTM, which might necessarily include face-to-face rheumatologic consultation with patients, suspected of having an undiagnosed connective tissue disease.
Second, it has previously been suggested that dynamic exchanges of clinical, radiologic and pathologic information between experts in a multidisciplinary process results in higher confidence diagnoses 5 . In the current study however, the proportion of high confidence diagnoses (70% or greater) assigned following MDTM evaluation did not increase when compared to the proportion of high confidence diagnoses being assigned by the individual components of the MDTM. In the majority of MDTMs, high confidence diagnoses were more frequently assigned by radiologists and pathologists, when compared to MDTM diagnoses or diagnoses assigned by clinicians. As radiologists and pathologists in the current study did not have access to clinical information, their interpretation was based almost entirely on pattern recognition, which might conceivably result in more confident, but not necessarily more accurate diagnoses. Although one benefit of the multidisciplinary process is that diagnoses may be challenged and must be publically defended, it is possible that extra discussion creates more difficulty in some cases that initially seem straightforward when evaluated by individuals in isolation. It must be highlighted however, that in the specific case of IPF, MDTMs made the diagnosis of IPF with high confidence more frequently than clinicians or radiologists.
Our methodology has some limitations. As patients were selected from a preantifibrotic drug era, IPF was possibly not as prevalent in our study group as it would be now at most referral centres which expend more time in evaluating patients for approval for anti-fibrotic treatment. However as discussed, this allowed us to evaluate the veracity of MDTM diagnosis for IPF, against outcome. Second, unlike a real-world multidisciplinary process, none of the observers had face-to-face consultation with patients and therefore did not have the benefit of obtaining a clinical history or performing physical examination first-hand. In difficult to characterize patients, a clinician's impression might conceivably be influenced by direct contact with the patient in ways, which are not easily and objectively quantified. Equally important, but also difficult to assess, is the impact of individual personalities on MDTM diagnosis.
Arguably a consensus diagnosis at multidisciplinary evaluation might sometimes reflect the strongest voice in the room rather than represent true agreement between participants. Lastly, the wide range of proportions of high confidence diagnoses demonstrated between the different MDTM's seen in our study may reflect cultural influences on the dynamics of multidisciplinary evaluation. These less tangible influences could be the focus of further studies.
In conclusion, our study demonstrates that diagnostic agreement between MDTMs is superior to interobserver agreement between clinicians, radiologists and pathologists in the setting of DPLD. In particular, inter-MDTM agreement for a diagnosis of IPF is good and validated by the greater prognostic significance of an IPF diagnosis made by multidisciplinary groups as compared to individual specialists.
Poor levels of inter-MDTM agreement were demonstrated for NSIP and hypersensitivity pneumonitis, the latter of which may relate to the lack of evidencebased guidelines for diagnosing this disease.
Research in context
Evidence before this study
We performed a PubMed search on 17 th January 2014 using the search terms "diffuse parenchymal lung disease", "idiopathic pulmonary fibrosis", "idiopathic interstitial pneumonias", "interobserver agreement", "diagnosis" and "multidisciplinary team" for the period between January 2000 and January 2014. This search was extended to 1 st December 2015 during the writing of the manuscript. Our search was restricted to publications written in English. We identified 7 key publications which were pertinent to our study 3-7,9,10 . Of these, 4 studies of observer agreement in setting of diffuse parenchymal lung disease were identified [5] [6] [7] 9 . All of these studies however predated the most up to date ATS/ERS update on the classification of the idiopathic interstitial pneumonias 4 , and not all of them evaluated diagnostic agreement between multidisciplinary teams but rather focused on diagnostic agreement between individual observers.
Added value of this study
This study is the first evaluation of inter-multidisciplinary team agreement for diagnosis in the setting of diffuse parenchymal lung disease since the updated 2013 ATS/ERS classification of the idiopathic interstitial pneumonias and the 2011 ATS/ERS/JRS/ALAT guidelines for the diagnosis and management of idiopathic pulmonary fibrosis.
Implications of all the available evidence
Our study demonstrates that diagnostic agreement between MDTMs is superior to interobserver agreement between clinicians, radiologists and pathologists in the setting of DPLD. Specifically in IPF, MDTMs have a higher level of agreement on diagnosis, assign diagnosis with higher confidence more frequently, and provide diagnoses that have greater prognostic significance than clinicians or radiologists in the majority of groups. This is of particular importance, as accurate and consistent diagnosis of idiopathic pulmonary fibrosis is needed if clinical outcome is to be optimised. In contrast, intermultidisciplinary team agreement for a diagnosis of hypersensitivity pneumonitis is poor, highlighting an urgent need for standardised diagnostic guidelines for this disease entity. 
